Stuttgart - Delayed Quote EUR

CARISMA Therapeutics Inc (W2J.SG)

Compare
0.4278 -0.0400 (-8.55%)
At close: December 19 at 8:16:46 AM GMT+1
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
20,268.0000
14,919.0000
9,834.0000
--
--
Operating Expense
87,042.0000
103,650.0000
65,996.0000
40,794.0000
28,378.0000
Operating Income
-66,774.0000
-88,731.0000
-56,162.0000
-40,794.0000
-28,378.0000
Net Non Operating Interest Income Expense
2,777.0000
1,936.0000
-3,145.0000
10.0000
29.0000
Other Income Expense
--
-84.0000
-1,919.0000
--
--
Pretax Income
-63,997.0000
-86,879.0000
-61,226.0000
-40,784.0000
-28,349.0000
Net Income Common Stockholders
-63,800.0000
-86,879.0000
-61,226.0000
-40,784.0000
-28,349.0000
Diluted NI Available to Com Stockholders
-63,800.0000
-86,879.0000
-61,226.0000
-40,784.0000
-28,349.0000
Basic EPS
-1.52
-2.59
-1.52
-1.01
-0.70
Diluted EPS
-1.52
-2.59
-1.52
-1.01
-0.70
Basic Average Shares
41,134.9150
33,524.1970
40,254.6660
40,254.6660
40,254.6660
Diluted Average Shares
41,134.9150
33,524.1970
40,254.6660
40,254.6660
40,254.6660
Total Operating Income as Reported
-66,774.0000
-88,731.0000
-56,162.0000
-40,794.0000
-28,378.0000
Total Expenses
87,042.0000
103,650.0000
65,996.0000
40,794.0000
28,378.0000
Net Income from Continuing & Discontinued Operation
-63,800.0000
-86,879.0000
-61,226.0000
-40,784.0000
-28,349.0000
Normalized Income
-63,800.0000
-86,795.0000
-59,307.0000
-40,784.0000
-28,349.0000
Interest Income
--
1,936.0000
--
10.0000
29.0000
Interest Expense
--
--
3,145.0000
--
--
Net Interest Income
2,777.0000
1,936.0000
-3,145.0000
10.0000
29.0000
EBIT
-66,774.0000
-88,731.0000
-58,081.0000
-40,794.0000
-28,378.0000
EBITDA
-63,367.0000
-85,894.0000
-56,188.0000
-40,112.0000
-27,930.0000
Reconciled Depreciation
3,407.0000
2,837.0000
1,893.0000
682.0000
448.0000
Net Income from Continuing Operation Net Minority Interest
-63,800.0000
-86,879.0000
-61,226.0000
-40,784.0000
-28,349.0000
Total Unusual Items Excluding Goodwill
--
-84.0000
-1,919.0000
--
--
Total Unusual Items
--
-84.0000
-1,919.0000
--
--
Normalized EBITDA
-63,367.0000
-85,810.0000
-54,269.0000
-40,112.0000
-27,930.0000
Tax Rate for Calcs
--
--
--
--
0.0001
12/31/2020 - 3/8/2023

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

2696.HK Shanghai Henlius Biotech, Inc.
23.900
+0.21%
 
ZNTL Zentalis Pharmaceuticals, Inc.
2.9300
+0.51%
 
ABSI Absci Corporation
2.9200
-3.95%
 
IBRX ImmunityBio, Inc.
2.6700
+0.75%